Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05447910 · ClinicalTrials.gov registry record
Analysis of Letrozole in Patients With Operable Hormone Receptor Positive, HER2 Negative Breast Cancer
A clinical trial, sponsored by Mayo Clinic.
- Terminated
- Registry status
- 21
- Enrollment target
NCT05447910: Clinical Trial study, sponsored by Mayo Clinic.
NCT05447910 is a clinical trial that was terminated before completion, run by Mayo Clinic. The registered enrollment target is 21 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05447910 was terminated before completion, sponsored by Mayo Clinic.
- TERMINATED
- Registry status
- 21 participants
- Enrollment target
Study Summary
The purpose of this study is to study to collect tissue samples from patients with early stage hormone receptor-positive HER2-negative breast cancer.
Interventions
- PROCEDURE Biospecimen Collection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2022-07-21 |
| Est. Completion | 2023-09-27 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05447910
The ClinicalTrials.gov registry entry for NCT05447910 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Biospecimen Collection is the first listed.
NCT05447910 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05447910 about?
NCT05447910 is a clinical study titled "Analysis of Letrozole in Patients With Operable Hormone Receptor Positive, HER2 Negative Breast Cancer". The purpose of this study is to study to collect tissue samples from patients with early stage hormone receptor-positive HER2-negative breast cancer.
What is the current status of trial NCT05447910?
This trial is currently terminated. The enrollment target is 21 participants. The study started on 2022-07-21. Estimated completion is 2023-09-27.
What interventions are being tested in trial NCT05447910?
The interventions under investigation include: Biospecimen Collection (PROCEDURE).
Who is sponsoring clinical trial NCT05447910?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.